latanoprostene bunod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| nitrogen monoxide (nitric oxide, NO) donors | 5261 | 860005-21-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 2, 2017 | FDA | BAUSCH AND LOMB INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye pain | 44.43 | 43.52 | 11 | 129 | 33843 | 63455039 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01EE06 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues |
| CHEBI has role | CHEBI:23018 | EC 4.2.1.1 inhibitor |
| CHEBI has role | CHEBI:35674 | antihypertensive drugs |
| CHEBI has role | CHEBI:39456 | antiglaucoma agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ocular hypertension | indication | 4210003 | DOID:9282 |
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.024% | VYZULTA | BAUSCH AND LOMB | N207795 | Nov. 2, 2017 | RX | SOLUTION/DROPS | OPHTHALMIC | 7629345 | Jan. 5, 2025 | REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| 0.024% | VYZULTA | BAUSCH AND LOMB | N207795 | Nov. 2, 2017 | RX | SOLUTION/DROPS | OPHTHALMIC | 7910767 | Jan. 5, 2025 | REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| 0.024% | VYZULTA | BAUSCH AND LOMB | N207795 | Nov. 2, 2017 | RX | SOLUTION/DROPS | OPHTHALMIC | 8058467 | Jan. 5, 2025 | REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| 0.024% | VYZULTA | BAUSCH AND LOMB | N207795 | Nov. 2, 2017 | RX | SOLUTION/DROPS | OPHTHALMIC | 7273946 | Oct. 3, 2025 | REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 8.60 | IUPHAR | SCIENTIFIC LITERATURE | |||
| Prostaglandin F2-alpha receptor | GPCR | Ki | 7.01 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| I6393O0922 | UNII |
| 4037152 | VANDF |
| C4279599 | UMLSCUI |
| CHEBI:63925 | CHEBI |
| CHEMBL2364612 | ChEMBL_ID |
| 11156438 | PUBCHEM_CID |
| DB11660 | DRUGBANK_ID |
| D10441 | KEGG_DRUG |
| 9629 | INN_ID |
| 9635 | IUPHAR_LIGAND_ID |
| 267110 | MMSL |
| 33340 | MMSL |
| 017395 | NDDF |
| 763040006 | SNOMEDCT_US |
| 763567008 | SNOMEDCT_US |
| CHEMBL1050 | ChEMBL_ID |
| 41639-83-2 | SECONDARY_CAS_RN |
| 6441636 | PUBCHEM_CID |
| 1988390 | RXNORM |
| C568859 | MESH_SUPPLEMENTAL_RECORD_UI |
| EJ85341990 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vyzulta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-504 | SOLUTION/ DROPS | 0.24 mg | OPHTHALMIC | NDA | 24 sections |